Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28331576 | 1.00 | TDP1 (0.43) | TDP1CYP2C19ALDH1A1FFAR3TSHR | |
| SCHEMBL29803938 | 1.00 | TDP1 (0.43) | TDP1CYP2C19ALDH1A1FFAR3TSHR | |
| SCHEMBL10710091 | 0.84 | TDP1 (0.47) | TDP1CYP2C19ALDH1A1FFAR3TSHR | |
| SCHEMBL10071034 | 0.79 | TDP1 (0.47) | TDP1CYP2C19ALDH1A1FFAR3TSHR | |
| SCHEMBL9234224 | 0.78 | LMNA (0.52) | TDP1 | |
| SCHEMBL16620753 | 0.78 | LMNA (0.46) | TDP1 | |
| SCHEMBL28333095 | 0.78 | LMNA (0.46) | TDP1 | |
| SCHEMBL19668472 | 0.77 | ALDH1A1 (0.50) | TDP1ALDH1A1 | |
| SCHEMBL9446932 | 0.77 | SLC22A6 (0.46) | TDP1 | |
| SCHEMBL15722826 | 0.77 | TDP1 (0.45) | TDP1CYP2C19ALDH1A1FFAR3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12427187-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| US-20220233647-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3980052-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3052134-B1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME (US) | 2021-05-05 | — | — | EP | disclosed |
| WO-2020247297-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3280450-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016164288-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9427475-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| EP-3052134-A2 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME LLC | 2015-04-16 | — | — | US | disclosed |
| WO-2015051052-A2 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427187-B2 | Glucose-responsive insulin conjugates | GPR119, IRS1, INSR | TDP1 4020/4885CYP2C19 3640/4885ALDH1A1 4239/4885 |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | TDP1 4593/4885CYP2C19 2552/4885ALDH1A1 3422/4885 |
| US-20220233647-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, IRS1, INSR | TDP1 4020/4885CYP2C19 3640/4885ALDH1A1 4239/4885 |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | TDP1 4519/4885CYP2C19 2464/4885ALDH1A1 3285/4885 |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | TDP1 4678/4885CYP2C19 2786/4885ALDH1A1 3459/4885 |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | TDP1 4519/4885CYP2C19 2464/4885ALDH1A1 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.